- Quote, Chart, News
- Snapshot
- Company Report
- Quotes
- Charts
- Key Developments
Recent News- Research
- SEC Filings
- Advisor FYI
- CAPS
- StockScouter
- Earnings Estimates
- Analyst Ratings
- Financial Results
- Insider Trading
- Ownership
- Message Board
- Guided Research
- Research Wizard
- Find Stocks
- Stock Screener
- Stock Power Searches
- Top-Rated Stocks
- Related Links
- Quote Watchlist
- Expert Picks
- E-mail & Alerts
- IPO Center
- Message Boards
- Capital Gains Analysis
News resources
| Incyte Corp (INCY) | 2 stories... |
| American International Group Inc (AIG) | 2 stories... |
| LM Ericsson Telephone ADR Reptg 1 Ord Shs Class B (ERIC) | 2 stories... |
| New York Times Co (NYT) | 1 story... |
| Ford Motor Co (F) | 1 story... |
| advertisement |
AstraZeneca ADR representing 1 Ord Shs: All Recent News
- Zacks Analyst Blog Highlights: Pozen, Sanofi-Aventis,... 11/23/2009
- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Business Wire
- Sage Advice On Vytorin 11/23/2009
- So what is the bottom line on the continuing kerfluffle over the cholesterol drugs Zetia and Vytorin, sold by Merck? The basic problem is this: What should patients and doctors do when insufficient data is collected on a new medicine? Merck has lots of studies showing that Zetia lowers cholesterol, but there are no studies that ... At Forbes
- U.S. Court of Appeals Upholds AstraZeneca AWP Settlement 11/20/2009
- Objector's arguments dismissed; ruling may speed settlements in other similar cases.BOSTON, Nov. 20 /PRNewswire/ -- The United States Court of Appeals for the First Circuit upheld an earlier... PR Newswire
- FDA OKs Abilify for autism-linked irritability 11/20/2009
- PRINCETON, N.J. (AP) - The U.S. Food and Drug Administration has approved top-selling Abilify as a treatment for autism-related irritability in children from the ages of 6 to 17, drug maker Bristol-Myers Squibb Co. said Friday. Associated Press
- Worse Than You Think 11/20/2009
- A look at how much of the $2.5 trillion the U.S. spends on health care goes down the drain. At Forbes
- This Baby Is a Nice Addition 11/20/2009
- A month into an acquisition, and Merck already sees a benefit. At Motley Fool
- AstraZeneca and the Philadelphia Department of Public Health... 11/20/2009
- WILMINGTON, Del., Nov. 20 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) and the Philadelphia Department of Public Health announced today at a press conference at Philadelphia Health Care Center... PR Newswire
- For Lilly's R&D Chief, a $2 Million Exit Handshake 11/19/2009
- ... At Wall Street Journal
- AstraZeneca Enters the Race for the Next Plavix 11/19/2009
- The pharmaceutical landscape is rapidly changing as patents for some of the blockbuster drugs of the last decade near expiration and other players try to grab some of the remaining revenues before generic medications flood the market. AstraZeneca (AZN) announced Thursday morning that it has filed a New Drug Application with the FDA for its antiplatelet treatment ticagrelor. The drug is meant to treat major cardiac events in patients with acute coronary syndrome (ACS) a disease that affects 2.4 million Americans according to the American Heart Association.The drug works by keeping platelets in... At Minyanville
- Moody's gives negative view on pharma credit 11/19/2009
- NEW YORK (AP) - Moody's Investors Service issued a negative opinion on the pharmaceutical industry Thursday, saying drugmaker credit ratings will be under pressure until early 2012 because they won't be able to fully replace revenue from best-sellers that go off-patent. Associated Press
- AstraZeneca seeks Brilinta approval in US 11/19/2009
- LONDON (AP) - AstraZeneca PLC said Thursday it has applied to U.S. regulators to market its blood clot preventer Brilinta, a potential new big seller for the company. Associated Press
- AstraZeneca submits Brilinta NDA to FDA 11/19/2009
- LONDON (MarketWatch) -- Drugmaker AstraZeneca said Thursday that it has submitted a new drug application to the U.S. Food and Drug Administration for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome. The proposed trade name for ticagrelor is Brilinta. At MarketWatch
- AstraZeneca Submits US New Drug Application for Ticagrelor... 11/19/2009
- WILMINGTON, Del., Nov. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for... PR Newswire
- Your Heart or Your Stomach? 11/18/2009
- It won't be a tough decision for patients to make. At Motley Fool
- Drug Lowers Cholesterol; Stock Follows 11/18/2009
- ISIS has a hard time at AHA despite good efficacy data. At Motley Fool
- More News
- Market Report
- News by Symbol
- Today's Investing Articles
- Breaking News
- News by Topic
- News by Industry
- MSNBC News
- Data providers
- Copyright © 2009 Thomson Reuters. Click for Restrictions.
- Quotes supplied by Interactive Data Real-Time Services.